IMSA101
Phase 2Small molecule
IMSA101 is one of 55 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.
1
Indications
5
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Kidney Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Thalomid
Bristol-Myers SquibbPhase 3
Afinitor
NovartisPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lenvima
EisaiPhase 3
Prolia
AmgenPhase 3
Depo-Provera
PfizerPhase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic NSCLC1 trial
Kidney Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMSA101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmuneSensor Therapeutics Inc.